IDEXX Laboratories, Inc. $IDXX Shares Sold by Acima Private Wealth LLC

Acima Private Wealth LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 69.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 449 shares of the company’s stock after selling 1,038 shares during the period. Acima Private Wealth LLC’s holdings in IDEXX Laboratories were worth $234,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Horizons Wealth Management purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $52,000. CX Institutional purchased a new stake in IDEXX Laboratories during the 3rd quarter worth $338,000. QRG Capital Management Inc. increased its holdings in IDEXX Laboratories by 16.8% in the 2nd quarter. QRG Capital Management Inc. now owns 3,323 shares of the company’s stock valued at $1,749,000 after purchasing an additional 477 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in IDEXX Laboratories by 2.7% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 28,991 shares of the company’s stock valued at $15,262,000 after purchasing an additional 761 shares in the last quarter. Finally, National Pension Service raised its position in IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after purchasing an additional 6,885 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 1.7%

IDEXX Laboratories stock traded up $8.68 during midday trading on Monday, hitting $527.07. 588,911 shares of the stock were exchanged, compared to its average volume of 569,073. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm has a market cap of $41.52 billion, a P/E ratio of 37.07, a P/E/G ratio of 2.77 and a beta of 1.55. The company has a 50 day moving average price of $543.61 and a two-hundred day moving average price of $555.14.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on IDXX shares. UBS Group boosted their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Finally, Citigroup upped their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $747.00.

Insider Buying and Selling

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.